risdiplam (Evrysdi) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease.   Wikipedia

Chemistry

  • SMILES: Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1
  • InChIKey: ASKZRYGFUPSJPN-UHFFFAOYSA-N
  • Mol. Mass: 401.47
  • ALogP: 1.96
  • ChEMBL Molecule:
    risdiplam  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$105.3193 - $137.8850
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ro7034067

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (3)


 

Atrophy

Muscular Atrophy, Spinal

Spinal Muscular Atrophies of Childhood (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Healthy Volunteers (Phase 1)

Muscular Atrophy, Spinal (Phase 4)

Spinal Diseases (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue